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Abstract
Background: Thyroid lymphomas are an exceptional finding in patients with thyroid nodules. Burkitt’s lymphoma is
one of the rarest and most aggressive forms of thyroid lymphomas, and its prognosis depends on the earliness of
medical treatment. Given the rarity of this disease, making a prompt diagnosis can be challenging. For instance,
fine-needle aspiration (FNA) cytology, which is the first-line diagnostic test that is performed in patients with
thyroid nodules, is often not diagnostic in cases of thyroid lymphomas, with subsequent delay of the start of
therapy.
Case presentation: Here we report the case of a 52-year-old woman presenting with a rapidly enlarging thyroid
mass. Thyroid ultrasonography demonstrated a solid hypoechoic nodule. FNA cytology was only suggestive of a
lymphoproliferative disorder and did not provide a definitive diagnosis. It is core needle biopsy (CNB) that helped
us to overcome the limitations of routine FNA cytology, showing the presence of thyroid Burkitt’s lymphoma.
Subsequent staging demonstrated bone marrow involvement. The early start of an intensive multi-agent
chemotherapy resulted in complete disease remission. At 60 months after the diagnosis, the patient is alive and has
not had any recurrence.
Conclusions: Clinicians should be aware that thyroid Burkitt’s lymphoma is an aggressive disease that needs to be
treated with multi-agent chemotherapy as soon as possible. To diagnose it promptly, they should consider to
order/perform a CNB in any patient with a rapidly enlarging thyroid mass that is suspicious for lymphoma.
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Background
Thyroid nodules are an extremely common occurrence.
It is estimated that up to 67% of the population has a
thyroid nodule that could be detected by ultrasonog-
raphy [1]. Thyroid cancer occurs in 7–15% of cases de-
pending on risk factors such as age, sex, family history,
and radiation exposure [2]. Thyroid lymphoma accounts
for less than 5% of all thyroid cancers. Nevertheless, cli-
nicians should know how to manage this extremely rare
occurrence, as the prognosis of the most aggressive sub-
types depends on the earliness of the diagnosis and the
subsequent start of multiagent chemotherapy regimens.
Routine medical work-up of patients with thyroid nod-
ules is based on the evidence that fine-needle aspiration
(FNA), preferably performed under ultrasonographic
guidance and with rapid on-site evaluation by a cytopa-
thologist [3], is the most sensitive and cost-effective
method to assess their nature and/or the need for sur-
gery [2, 4–6]. By contrast, FNA has a low accuracy for
the diagnosis of thyroid lymphomas [7, 8], often leading
to diagnostic surgery. It has been argued that in cases
suspicious of thyroid lymphomas, core needle biopsy
(CNB) could help to reduce diagnostic surgery [7] and,
most importantly, to obtain earlier the diagnosis
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necessary to start life-saving treatment with multiagent
chemotherapy.
Here we report the case of a woman with Burkitt’s
lymphoma of the thyroid gland, where CNB helped us to
overcome the limitations of routine FNA cytology and
to prescribe the right medical treatment. We also per-
formed a review of the literature and a search in
Pubmed of other clinical cases of adult patients affected
by Burkitt’s lymphoma of the thyroid gland. For this pur-
pose, we used the combined terms “Burkitt”, “thyroid”,
and “case”, and we selected only English written articles
[9–24], while we excluded a few reports in other lan-
guages, such as Spanish [25–28], French [29, 30], and
Japanese [31, 32].
Case presentation
A 52-year-old woman presented to our Endocrinology
Unit with a growing thyroid mass, which had enlarged
so rapidly she had become unable to wear her motor-
cycle helmet in the weeks prior to her visit. She suffered
from Hashimoto’s thyroiditis for which she was taking
levothyroxine. There was no history of neck irradiation
or family history of thyroid cancer. On examination,
there was a large, firm thyroid nodule on the right side
of the neck, without palpable cervical lymphadenopathy.
TSH was 4.79 μU/mL with FT3 and FT4 within the ref-
erence range. Otherwise, there was only a mild
thrombocytopenia. Thyroid ultrasonography showed a
solid hypoechoic nodule in the right lobe of the gland,
with significant internal vascularity and absence of calci-
fications (Figure 1). FNA cytology with rapid on-site
evaluation of the material adequacy showed that there
were only atypical lymphoid cells with no thyrocytes and
the specimens were considered suggestive of a lympho-
proliferative disorder but insufficient to make a diagno-
sis, such that a CNB was scheduled for the following
day.
After checking the blood coagulation profile, the pa-
tient underwent a CNB, which allowed histological/mor-
phological tissue analysis. This showed that normal
thyrocytes were virtually all replaced by homogeneous
medium-sized lymphocytes with scanty blue cytoplasm,
round nuclei, coarse chromatin, and multiple small nucle-
oli. There were frequent mitotic figures and scattered
macrophages ingesting apoptotic cells, giving to the tissue
section the so-called ‘starry sky’ appearance (Fig. 1). Over-
all, these features were consistent with the presence of a
thyroid Burkitt’s lymphoma, and further investigations
were ordered to confirm the diagnosis and evaluate the
disease extent. A CT of chest and abdomen showed the
44x43x87 mm thyroid nodule with left tracheal deviation
(Figure 1) without other visible masses or lymph nodes.
Bone marrow biopsy showed almost 100% lymphoid infil-
tration, consisting of a population of intermediate-sized
blast-like cells, with prominent nucleoli, which were re-
placing all normal cells. These cells expressed CD10,
CD20, and were negative for Bcl2, CD34, and TdT.
Altogether these results led us to the final diagnosis of
stage IV Burkitt’s lymphoma [33].
The patient was admitted to our hospital’s Haematol-
ogy Unit and was successfully treated with 3 cycles of
Hyper-CVAD chemotherapy (cyclophosphamide, vincris-
tine, doxorubicin and dexamethasone) completed in five
months. The thyroid mass disappeared (Fig. 1) and the
platelets returned to baseline levels. At 60 months after
diagnosis the patient is alive, and remains disease-free at
regular follow-up.
Discussion
Burkitt’s lymphoma is one of the rarest [34] and also most
aggressive subtypes of thyroid lymphomas [11]. It is con-
sidered the fastest growing human tumor, with a cell
doubling time of 24–48 h [33]. It arises from B cells,
where a chromosomal translocation, more frequently
t(8;14)(q24;q32) and less frequently either t(2;8)(p12;q24)
or t(8;22)(q24;q11), leads to the deregulated expression of
the oncogene C-Myc, which promotes cell cycle progres-
sion [35]. As a result, this lymphoma is characterized by
the presence of monomorphic medium-sized B cells with
a very high proliferation rate and increased apoptosis. To
the best of our knowledge, 23 cases of thyroid Burkitt’s
lymphoma have been described in the English medical lit-
erature [9–24] (Table 1). The majority of them (13 out of
23) were cases of Burkitt’s lymphoma with disseminated
disease (stage III/IV). Among them, at least 5 patients
(22%) died within the first 2 years of follow-up [11, 21, 22,
24] (Table 1). These were cases of age greater than
60 years, advanced disease, or disease onset complicated
by cavernous sinus thrombosis (Table 1). Consistent with
this, advanced age, poor performance status, advanced
stage, and central nervous system or bone marrow in-
volvement are considered the most relevant prognostic
factors of a poor outcome in Burkitt’s lymphoma [35].
Therefore, starting chemotherapy as soon as possible is
key for a complete response.
Unfortunately, given the rarity of this disease, making
a prompt diagnosis can be challenging. The first aspect
that should raise the suspicion of a thyroid lymphoma
should be the presence of a rapidly growing goiter or
nodule. It is estimated that 70% of patients with aggres-
sive thyroid lymphomas complain of a rapidly expanding
cervical mass that causes obstructive symptoms, such as
dyspnea and dysphagia [8, 36]. In line with this figure,
these symptoms were reported by 65% (15 out of 23) of
patients with thyroid Burkitt’s lymphoma (Table 1).
However, these symptoms are not specific and they
might also be due to other conditions, such as anaplastic
carcinoma or Riedel’s thyroiditis. Moreover, sometimes,
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the thyroid mass due to a lymphoma can be an inciden-
tal occurrence in patients with fever, malaise, weight
loss, or hypothyroidism due to Hashimoto’s thyroiditis,
as reported by [9, 16, 20]. Otherwise, there have been
also a few reports of exceptional presentations such as a
pathological fracture due to a secondary lytic lesion [13],
and the onset of diplopia and headache due to a bilateral
cavernous sinus thrombosis [24].
According to current guidelines [2, 6], ultrasonography
is the first exam that should be performed in patients
with a goiter or a thyroid nodule, and it should be gener-
ally followed by FNA cytology, whenever a solid thyroid
nodule greater than 1-2 cm is detected. However, in case
of a thyroid lymphoma, these procedures are often non-
diagnostic. For instance, the ultrasound features of thy-
roid lymphomas, which include very low echogenicity,
enhanced posterior echoes, increased vascularity, and
lack of internal calcifications, are all aspecific [36]. In
addition, as shown by the rapid on-site evaluation of our
specimens, FNA cytology is often suggestive but insuffi-
cient to make a diagnosis of thyroid lymphoma. Apart
from not providing adequate material, other pitfalls of
FNA include the cytological similarities with thyroiditis
and the high rate at which both pathologies occur simul-
taneously in the same gland, as 60–90% of lymphomas
arise on a background of thyroiditis [36]. For these reasons,
it has been argued that patients with suspected thyroid
lymphomas require CNB or excision for diagnosis [8].
Tissue biopsies can provide the material necessary to
assess tissue morphology and to perform a panel of
immunostains, which should be the first aspects to
evaluate when a Burkitt’s lymphoma is suspected [37]. In
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C D
E F
Fig. 1 Endocrine imaging of a patient with Burkitt’s lymphoma. Thyroid US showed a solid hypoechoic mass (a) with significant internal
vascularity (b) and no calcifications. Core needle biopsy showed homogeneous medium-sized B cells infiltrating the thyroid (c, arrowhead),
mitotic figures (c, asterisk), and scattered macrophages ingesting apoptotic cells (c, arrow), giving a “starry sky” appearance. The extent of thyroid
infiltration can be appreciated on (d) where follicular cells are only those positively stained for TTF1 (thyroid transcription factor 1). The CT scan
performed before treatment showed a 44x43x87 mm thyroid nodule (e), which disappeared at the CT scan performed one year after treatment
completion (f)
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particular, typical morphological features of this lymph-
oma include the presence of homogeneous medium-sized
lymphocytes with round nuclei, coarse chromatin and
multiple small nucleoli, surrounded by a scanty blue cyto-
plasm with frequent small vacuoles and indistinct edges
[38]. Another typical feature is the “starry sky” pattern
[16], which is due to the presence of macrophages con-
taining apoptotic tumor cells on a background of prolifer-
ating B cells. Then, to reach a final diagnosis of Burkitt’s
lymphoma, immunohistochemical stainings should pro-
vide evidence that lymphomatous cells express CD19,
CD20, CD10, and CD79a and no CD3, CD5, Bcl2, and
Table 1 Reported cases of thyroid Burkitt’s lymphomas
Authors (ref) Age
(y)
Sex
Sites of involvement Stage Symptoms (S)
Diagnosis (D)
Follow-
up (mo)
Outcome
Thieblemont
[9]
46 M Thyroid, cervical and mediastinal nodes,
bone marrow, stomach
IV S: asymptomatic
D: CNB
NA NA
Iqbal [10] 6 M Thyroid, right atrium, right ventricle,
pericardium, abdominal masses, CNS
IV S: thyroid enlargement, anorexia,
weight loss, shortness of breath
D: biopsy of suprarenal mass
NA Alive, CR
Ruggiero
[11]
40 F Thyroid, other sites IV S: obstructive symptoms
D: FNA + CNB
Died after 3 months
Kalinyak [12] 53 M Thyroid, bone marrow IV S: obstructive symptoms
D: FNA + bone marrow
27 Alive, CR
Camera [13] 56 M Thyroid, mediastinum, kidneys, right femur IV S: pathological fracture
D: FNA + open surgery
NA Reduction of all
lesions
Kandil [14] 60 F Thyroid and cervical nodes I S: obstructive symptoms
D: FNA + incisional biopsy
NA Succesfully treated
after 1 cycle of CT
Yildiz [15] 31 M Thyroid, cervical and jugulodigastric nodes I S: obstructive symptoms
D: open surgery
6 Alive, CR
Bongiovanni
[16]
72 F Thyroid, cervical nodes, liver and skeletal
lesions
IV S: fever
D: FNA + CNB
NA NA
Mweempwa
[17]
58 F Thyroid I S: obstructive symptoms
D: FNA + CNB
4 Alive, CR
Albert [18] 16 M Thyroid I S: obstructive symptoms
D: open surgery
NA Alive, CR
Zhang [19] 8 M Thyroid I S: obstructive symptoms
D: open surgery
48 Alive, CR
Cooper [20] 14 M Thyroid, lung, kidney and pancreas IV S: malaise, lethargy, weight loss
D: FNA + OWB
36 Alive, CR
Alloui [21] 70 M Thyroid I S: obstructive symptoms
D: CNB
Patient died of septic shock
after 17 days
Quesada [22] 24 NA Thyroid, cervical, aortcaval, preaortic, and
paraortic nodes
III S: obstructive symptoms 5/7
D: FNA 5/7 + either CNB 4/7, or open
surgery 3/7
41 Alive, CR
28 NA Thyroid and cervical nodes I 361 Alive, CR
47 NA Thyroid, cervical nodes, CNS IV 25 Alive, CR
45 NA Thyroid I 12 Alive, PD
41 NA Thyroid, cervical, pretracheal and retrocrural
nodes, mediastinum, bone marrow
IV 113 Alive, CR
49 NA Thyroid, cervical and iliac nodes III Died after 12 months
19 NA Thyroid, cervical, jugulodigastric nodes,
lumbar vertebrae
IV Dieta after 23 months
Akshintala
[23]
21 F Thyroid and cervical nodes I S: obstructive symptoms
D: CNB + incisional biopsy
NA Alive, CR
Moghaddasi
[24]
47 F Thyroid and cervical nodes I S: diplopia
D: incisional biopsy
Died after 30 days
Claudi [45] 56 F Thyroid, liver IV S: obstructive symptoms
D: open surgery
NA NA
CNB is for core needle biopsy; CNS is for central nervous system; CR is for complete remission; FNA is for fine needle aspiration; NA is for not applicable; PD is for
persistent disease; OWB is for open wedge biospy
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TdT [37, 38]. Additional diagnostic criteria for Burkitt’s
lymphoma include Ki67 positivity/proliferation index >
90%, light chain restriction, nuclear c-myc positivity at im-
munocytochemistry, and t(8;14)(q24;q32) by fluorescence
in situ hybridization [38], as reported by [9, 11, 16, 17,
21–23] (Table 1).
Core needle biopsy (CNB) is an exam that is not rou-
tinely performed in the work-up of patients with thyroid
nodules. This is ascribed to higher cost, technical re-
quirements, and concerns about potential complications
as compared to FNA [39]. In addition, also CNB can fail
to diagnose follicular carcinomas [40], whose presence is
diagnosed based on vascular invasion and/or capsular
breakthrough [39]. Consistent with these issues, the
AACE/ACE/AME guidelines suggest considering the use
of CNB only in solid nodules with persistently inad-
equate cytology [6], and the ATA guidelines do not even
recommend its use [2]. Nevertheless, our case reminds
that CNB should not be dismissed as it can become ex-
tremely useful in cases of thyroid lymphomas, where it
allows to obtain a specimen that is adequate for histo-
logical/morphological tissue analysis, as well as for other
key diagnostic tests. This is supported also by our litera-
ture review showing that CNB (but no FNA) was able to
provide the final diagnosis without additional exams [9,
11, 16, 17, 21–23] (Table 1). In particular, in the 23 re-
ports of Burkitt’s lymphoma, FNA cytology was per-
formed in 12 patients (52%) and was able to provide the
diagnosis without core needle or open surgical biopsy
only in one case [12] (Table 1). Overall, in the reported
cases of thyroid Burkitt’s lymphoma, diagnosis was pro-
vided by core needle biospy (43%; 10 cases out of 23),
open surgery (35%; 8 cases out of 23), incisional/open
wedge biopsy (17%; 4 cases out of 23), rarely by FNA (1
case out of 23) [12] or biopsy of other sites of involve-
ment, such as a renal mass (1 cases out of 23) [10]
(Table 1).
In line with the concept that CNB should be the ad-
vised modality for thyroid lymphoma diagnosis, Sharma
and colleagues have recently shown that CNB diagnostic
sensitivity for detecting thyroid lymphomas is 93% [41].
This is in line with the results of Ha and colleagues, who
found that CNB sensitivity for thyroid lymphoma was
94.7% with a positive predictive value of 100%, such that
CNB was able to significantly reduce the rate of diagnos-
tic surgery from 37.9 to 5.3%, as compared to FNA [7].
Interestingly, in a work comparing CNB to open surgical
biopsy in patients with lymphoadenopathies, CNB
turned out to have greater sensitivity for detecting ma-
lignancy, and it was also faster, cheaper and safer than
the conventional surgical approach [42].
Having said that, current treatment of Burkitt’s lymphoma
in adults is based on the delivery of short-duration,
dose-intensive, multi-agent chemotherapy with minimization
of treatment delays, and maintenance of serum drug concen-
trations over at least 48 to 72 h [35]. Some protocols, like the
French LMB, the German BFM, and the CODOX-M/
IVAC [43], have been adapted from pediatric regimens.
Others, such the Hyper-CVAD regimen [44], which is the
one we used, have been evaluated primarily in adults, but
incorporate the principles found to be effective in
pediatric populations [35]. Overall, with these regimens,
65 to 100% of patients achieve a complete response and
47 to 86% of patients maintain these remissions at least
1 year after treatment completion [35].
Conclusions
This case describes a patient with thyroid Burkitt’s lymph-
oma, which is a rare and highly aggressive thyroid malig-
nancy that requires a prompt diagnosis in order to start as
soon as possible life-saving multi-agent chemotherapy. In
particular, our case highlights the usefulness of CNB for
the diagnosis of thyroid lymphomas and reminds clini-
cians to order/perform it in any patient with a rapidly en-
larging thyroid mass that is suspicious for lymphoma.
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